SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to renewed excitement around its AI capabilities and government contracts, particularly a recent Navy deal, sparking discussions of a gamma squeeze and potential for significant share price appreciation. The community is buzzing about the company's growth prospects and potential to disrupt traditional software companies, while some remain skeptical about its valuation and long-term sustainability. Others are pointing to insider activity and technical indicators as signals.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors dissect earnings, which revealed increased profitability despite a revenue decline attributed to strategic store closures and hardware sales slump. Community debates center on the significance of these results, with some highlighting the surge in collectibles revenue and potential for future growth, while others express concern over the company's direction and overall market sentiment towards meme stocks.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

AFJK is trending due to a massive intraday surge, with some traders reporting gains of over 900%. Community members are discussing the potential for overnight holding and comparing the move to other high-flying stocks, while also noting the stock's volatility and halt-filled trading session.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences ($ENVB) is trending due to community discussion around its low float and potential for a significant price move, with some traders drawing comparisons to other volatile stocks. Chatter includes speculation on news catalysts, potential for a short squeeze, and discussion of their patented intellectual property. Some investors are closely monitoring the stock for breakout opportunities while others caution about potential risks associated with low-float stocks.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SUGP is trending as traders discuss its low float and potential for a significant squeeze, drawing comparisons to recent runners like $ENVB and $SMX. Community members are actively watching for a breakout above key price levels, with some speculating about a short squeeze. The stock's volatile price history and potential for quick gains are also fueling interest.

Lion Group Holding Ltd. operates an all-in-one, state-of-the-art trading platform that offers a wide spectrum of products and services. It operates through the following segments: Futures and Securities Brokerage Services, Contract-For-Difference (CFD) Trading, Total Return Service (TRS) Trading and OTC Stock Option Trading. The company was founded by Jian Wang in 2015 and is headquartered in Singapore.

Lion Group Holding Ltd - ADR

Lion Group Holding Ltd

LGHL is trending due to discussions around potential short squeezes and comparisons to other high-flying low floaters like $AFJK and $SMX. The community is focused on its low float and potential for significant gains, while also debating whether it's a legitimate opportunity or just another pump and dump. Some are pointing to the company's Bitcoin holdings as a catalyst.

Oriental Culture Holding Ltd. operates as a holding company, which is engaged in providing collectibles and artwork e-commerce services through its subsidiaries. The firm facilitates trading by individual customers of all kinds of collectibles, artwork, and certain commodities on its online platform owned by its subsidiary in Hong Kong, namely the China International Assets and Equity of Artworks Exchange Limited. It provides services including investor education, market information, customer support, and technology infrastructure. The company was founded in March 2018 and is headquartered in Hong Kong.

Oriental Culture Holding Ltd

OCG is trending due to significant price and volume surges, reminiscent of other Hong Kong stocks that have experienced similar runs. Community members are discussing the stock's impressive gains and potential for further upside, while also weighing the risks associated with pump-and-dump schemes often seen with such stocks. Some traders highlight the high trading volume and are watching for continued momentum.

Greenwave Technology Solutions, Inc. is an emerging growth company, which engages in recycling ferrous metal. It also recycles nonferrous metals including aluminum, copper, stainless steel, nickel, brass, titanium, lead, alloys, and mixed metal products. The company was founded on April 26, 2013 and is headquartered in Chesapeake, VA.

Greenwave Technology Solutions Inc

GWAV is trending as traders discuss potential earnings, delayed filings, and the possibility of a short squeeze due to its low float. Some are optimistic about the company's recycling operations and potential for high gains, while others express concerns about its financials and past reverse splits. The community is actively debating the stock's future direction amid mixed opinions on management and company prospects.

Horizon Space Acquisition I Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on June 14, 2022 and is headquartered in New York, NY.

Horizon Space Acquisition I Corp

Horizon Space Acquisition I Corp (HSPO) is trending due to volatility, potentially fueled by its status as a low-float SPAC. The community is actively discussing its extreme price swings and comparing it to other high-flying stocks, while also noting the company's announcement of a voluntary delisting from the Nasdaq.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is trending amid mixed sentiment, fueled by discussions around production, sales, and comparisons with competitors like NIO and Xpeng. Community members are actively debating the company's performance in the EV market and its strategic direction, including their pricing and new model launches. Furthermore, there are active debates about production quality, delivery numbers, and future expectations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Predictive Oncology Inc. (POAI) drew significant interest from retail investors after the company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million, which will support its adoption of a digital asset treasury strategy.The firm stated that the principal holding will be the native utility token of the Aethir ecosystem.The two private transactions are expected to close on or about October 2. The funds will be used to support the company’s digital asset treasury strategy, for the acquisition of ATH in the open market, and for working capital and general corporate purposes, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-inc-announces-private-placements-344-million">stated</a>.Last week, Predictive Oncology also <a href="https://stocktwits.com/news-articles/markets/equity/predictive-oncology-shares-tumble-on-reverse-stock-split-announcement/chDl1r4R3IR">announced</a> a 1-for-15 reverse stock split of its issued and outstanding shares of common stock, which became effective at 12:01 a.m. on Tuesday, Sept. 30, 2025. The split is designed to bring the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the exchange. Following the split, the company lowered its shares of common stock to 762,000 from over 11.4 million.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/POAI">POAI stock</a> rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Predictive Oncology is an AI-driven drug development and discovery company. For the second quarter, the company reported diluted loss per common share of $0.22. The company ended the quarter with $506,078 in cash and cash equivalents, compared to $611,822 as of Dec. 31, 2024, and a stockholders' deficit of approximately $1.7 million.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-spotify-stock-is-slipping-2-in-premarket/chDDP1nR3Bg">Why Spotify Stock Is Slipping 2% In Premarket</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Predictive Oncology Stock Receives Significant Investor Interest Today – Here Are Two Important Developments

The company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million.

Equity

The company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million.


Shares of Predictive Oncology Inc. (POAI) tumbled 19% on Thursday after the company announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock.The reverse stock split will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/25/3156239/37244/en/Predictive-Oncology-Announces-1-for-15-Reverse-Stock-Split.html">become</a> effective at 12:01 a.m. on Tuesday, September 30, the company said. The reverse stock split is primarily aimed at bringing the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the bourse.At the effective time of the reverse stock split, every 15 shares of Predictive Oncology’s issued and outstanding common stock will be combined automatically into one share of common stock. While the company currently has over 11.4 million shares of common stock, it will be reduced to about 762,000 after the split, the firm added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/POAI">POAI stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_2_16_32_PM_png_9c3fdd1117.webp" alt="POAI's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>POAI's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock will fall below $0.50 before the reverse stock split becomes effective.<stembedurl>https://stocktwits.com/MillionaireTrader555/message/629988968</stembedurl>Predictive Oncology is an AI-driven drug development and discovery company. For the second quarter, the company reported diluted loss per common share of $0.22. The company ended the quarter with $506,078 in cash and cash equivalents, compared to $611,822 as of December 31, 2024, and a stockholders' deficit of approximately $1.7 million.POAI stock is up 17% this year and approximately 22% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tiziana-life-sciences-stock-rises-on-advancing-second-asset/chDl0MtR34z">Tiziana Life Sciences Shares Rise On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Predictive Oncology Shares Tumble 19% On Reverse Stock Split Announcement – More Details Inside

The reverse stock split is primarily intended to bring the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the exchange.

Shares of Predictive Oncology Inc. (POAI) fell to their lowest level in a month on Thursday, drawing&nbsp;significant retail attention. Renovaro announced that its 2025 lawsuit to enforce a merger agreement with POAI will proceed on an expedited trial schedule.Renovaro, a TechBio company specializing in diagnostics and genetically enhanced cancer therapies, said the Delaware Court of Chancery approved its motion to fast-track a&nbsp;lawsuit filed earlier this month.&nbsp;Predictive Oncology shares closed down 10.1% at $0.98 on Thursday, holding steady in after-hours trading.The case stems from an alleged breach of a binding merger agreement signed on Jan. 1.According to Renovaro’s complaint, the agreement required POAI to merge into Renovaro in exchange for a new class of preferred stock.&nbsp;Renovaro claims that Predictive Oncology violated exclusivity and good faith clauses by raising $545,000 in a public offering in February and attempting to terminate the agreement unilaterally in April.The company&nbsp;now seeks specific performance, injunctive relief, and damages for the alleged breaches.In its Form 10-Q filing dated May 14, Predictive Oncology said that while the two companies entered into a binding letter of intent for the merger on Jan. 1, and extended the agreement’s termination date to March 31, no definitive purchase agreement was signed by that date.&nbsp;Predictive Oncology’s board notified Renovaro on April 3 that merger discussions were discontinued and that the company has no further obligations under the letter of intent or extension agreement.&nbsp;The company dismissed Renovaro’s lawsuit as without merit and said it intends to “vigorously” contest the case.The dispute unfolds as Predictive Oncology continues to promote its use of AI and machine learning in drug discovery, citing access to a biobank of over 150,000 live tumor samples.&nbsp;The company said its platform modeled tumor responses for 21 previously untested compounds.On Stocktwits, retail sentiment was ‘bullish’ amid a 2,200% surge in 24-hour message volume.One retail user said they held no position in POAI but were invested in Renovaro and hoped the merger would be completed.&nbsp;<stembedurl>https://stocktwits.com/Stengaard1/message/615590359</stembedurl>Another user suggested POAI could deliver unexpected gains, predicting the stock might rally suddenly.<stembedurl>https://stocktwits.com/EarlofLondon/message/615526666</stembedurl>The stock has risen 6.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish

Renovaro said the Delaware Court of Chancery had approved an expedited trial schedule for the lawsuit it filed to enforce a binding merger agreement with Predictive Oncology.

Investors Eye Biotech Sector as Cancer Therapy Market Surges

Investors Eye Biotech Sector as Cancer Therapy Market Surges Investors Eye Biotech Sector as Cancer Therapy Market Surges PR Newswire VANCOUVER, BC, Feb. 19, 2025 USA News Group News CommentaryIssued...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SSTK, AKYA, POAI on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SSTK, AKYA, POAI on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SSTK, AKYA, POAI on Behalf of Shareholders...

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ACCD, SHOT, POAI, FUBO on Behalf of Shareholders

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ACCD, SHOT, POAI, FUBO on Behalf of Shareholders SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ACCD, SHOT, POAI, FUBO on Behalf of Shareholders...

PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick and Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SSY, FUBO, RHE, POAI on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SSY, FUBO, RHE, POAI on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SSY, FUBO, RHE, POAI on Behalf of...

POAI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Predictive Oncology Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Predictive Oncology Inc. (NASDAQ: POAI) to Renovaro Inc. is fair to Predictive shareholders. Halper Sadeh...

Why Predicitive Oncology Stock Is Soaring

Predictive Oncology shares are blasting higher Thursday after the company announced it is expanding its AI and machine learning driven drug discovery platform to pursue discovery of novel biomarkers...

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

POAI
Predictive Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest POAI News

POAIPredictive Oncology Inc